Status
Conditions
Treatments
About
The path of a patient depends largely on his health care network, that is to say of the interrelationships between health professionals who will be involved throughout his career. At the hospital, the transition points in the care process is a vulnerable time for the patient regarding the continuity of his medication. These transition points are the intake, the transfer and the outlet. In town, our health system must be able to build on the inter-city hospital, warranty essential guarantee of the continuity of care. However, there is often a breakdown in this relationship with more or less serious consequences ranging from simple dissatisfaction of the patient, to the realization of duplicate examinations or the use unjustified emergency and re-hospitalization. Medication errors can occur, resulting from incomplete information or poorly communicated in this city hospital interface.
The city hospital dysfunctions are mainly organizational, hospital being rather specialized therapeutic approach centered on pathology and medicine city instead focuses on a patient's overall approach.
The involvement of the pharmacist in the hospital, as the city is an interesting axis to develop. In town, the pharmaceutical nomadism, including in major cities remains low, patients generally have a dedicated pharmacies for the treatment of their serious or chronic pathologies. The development of the pharmaceutical folder today allows the pharmacies to access the history and the entire therapy of patients prescribed to town by different specialists and general practitioners, on the last 4 months. Its recent availability within our hospital Group allows us to consider its use to fully optimize the patient's drug monitoring.
Full description
Hypothesis The involvement of hospital pharmacists from the admission of the patient in the oncology department until its release, with a comprehensive review of its treatment and anticipation of therapeutic needs when returning home and a joint organized with the community pharmacist and doctor, reduces the rate of drug discontinuity and thus improve its therapeutic management.
Goal
The investigators want to integrate and evaluate clinical pharmacist activities at different stages of the patient care process transition points:
The admission by drug conciliation to determine exhaustively the medication history and the observed differences, and assess the patient's treatment adherence, to consider a revision of the treatment if necessary
During the stay by daily pharmaceutical validation of drug prescriptions made in DxCare to play down the drug iatrogenic and participate in the definition of pharmacotherapy,
In preparation for the release of the drug per patient reconciliation to inform and advise the patient about treatment and communicate relevant information to the city of health professionals.
/ DRUG RECONCILIATION TO ENTRY
Goal Detect differences in prescription between the city and the hospital in establishing a complete and exhaustive list of treatments taken by the patient before hospitalization, avoiding medication errors, appearance starting point EIG.
procedure The hospitalization of Medical Oncology Service has 20 beds (14 traditional hospital beds and six weeks of hospital beds) with an average rate of entries per day of 3-4 patients, 1 to 2 per week are new patients. Patients will be seen by a hospital pharmacist within <24h of admission, or <72 h during late entry on Friday, Saturday, and Sunday morning.
/ The reconciliation begins with a review of treatments called Bilan Medicated Optimized (BMO). The list to be drawn regarding medications taken by the patient whether prescribed or not. To formalize, it is necessary to conduct an interview with the patient and / or his entourage as well as city health professionals or other care facilities if any. The first source of information is that we will exploit the patient's pharmaceutical record (if open), accessible via its vital card and resuming treatment provided during the last 4 months. If drugs are brought home by the patient, they are another useful source of information. BMO This will be achieved in 2 ways:
/ The differences observed may be unintentional (medication errors) and correspond to involuntary treatment changes and are likely to generate an adverse event for the patient, or intentional but not documented and correspond to voluntary changes in treatment, the reasons are not indicated in the patient file. It may be an addition, modification or interruption of a medicament. This lack of information is likely to generate a medication error later. The characterization of the differences will result in 3 steps:
/ The finalized conciliation document is then validated by the hospital pharmacist and ends up embedded in the patient record to be reused during a transfer or discharge.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal